Table 2.
Clinical outcomes
| Total (n = 755) | ATO group (n = 382) | Non-ATO group (n = 373) | HR (95% CI) | P value | |
| probability, % (95% CI) | probability, % (95% CI) | probability, % (95% CI) | |||
| 3-y DFS | |||||
| Low risk | 97.6 (95.3–100) | 100 | 95.1 (90.5–99.9) | NA | 0.012 |
| Intermediate risk | 96.8 (94.9–98.7) | 97.1 (94.6–99.6) | 96.5 (93.8–99.3) | 1.17 (0.39–3.47) | 0.781 |
| High risk | 90.4 (86.6–94.3) | 93.2 (88.7–97.9) | 87.4 (81.5–93.8) | 0.52 (0.22–1.24) | 0.14 |
| Total | 95.0 (93.4–96.6) | 96.5 (94.7–98.4) | 93.4 (90.9–96.0) | 0.55 (0.29–1.04) | 0.066 |
| 7-y DFS | |||||
| Low risk | 95.9 (92.7–99.2) | 100 | 91.6 (85.2–98.4) | NA | 0.012 |
| Intermediate risk | 95.8 (93.6–98.1) | 95.2 (91.7–98.8) | 96.5 (93.8–99.3) | 1.17 (0.39–3.47) | 0.781 |
| High risk | 90.4 (86.6–94.3) | 93.2 (88.7–97.9) | 87.4 (81.5–93.8) | 0.52 (0.22–1.24) | 0.14 |
| Total | 94.2 (92.4–95.9) | 95.7 (93.6–97.9) | 92.6 (89.8–95.4) | 0.55 (0.29–1.04) | 0.066 |
| 7-y OS | |||||
| Low risk | 98.4 (96.1–100) | 100 | 96.7 (92.2–100) | NA | 0.150 |
| Intermediate risk | 97.8 (96.0–99.6) | 96.9 (93.8–100) | 98.7 (97.0–100) | 1.96 (0.36–10.69) | 0.438 |
| High risk | 94.9 (91.9–97.9) | 94.5 (90.3–98.9) | 95.3 (91.3–99.4) | 1.11 (0.34–3.64) | 0.864 |
| Total | 97.0 (95.7–98.4) | 96.9 (94.9–98.8) | 97.2 (95.4–99.1) | 1.07 (0.44–2.63) | 0.883 |
| 7-y CIR | |||||
| Low risk | 2.9 (1.3–6.7) | 0 | 6.6 (2.6–16.9) | NA | <0.001 |
| Intermediate risk | 2.4 (1.2–4.9) | 1.2 (0.3–4.5) | 3.5 (1.7–7.1) | 0.34 (0.07–1.68) | 0.186 |
| High risk | 7.6 (4.9–11.7) | 5.1 (2.5–10.4) | 9.9 (6.1–16.1) | 0.50 (0.19–1.35) | 0.173 |
| Total | 4.1 (2.8–6.1) | 2.2 (1.1–4.2) | 6.1 (3.9–9.5) | 0.35 (0.16–0.79) | 0.011 |
The Kaplan–Meier method was used to estimate the survival above. Treatment protocol of ATO group (Low risk: ATRA+ATO, Intermediate risk: ATRA+ATO, High risk: ATRA+ATO+IDA/DNR). Treatment protocol of non-ATO group (Low risk: ATRA+IDA/DNR, Intermediate risk: ATRA+IDA/DNR, High risk: ATRA+IDA/DNR+Ara-C). NA, not applicable.